Cross-Sector entity
Michael McGarrity is most often covered alongside Baldwin, which appears in 2 of these 3 stories. earnings accounts for 1 of the 3 tracked stories, while 2 other categories carry the remainder. We currently track 3 Cross-Sector stories that mention Michael McGarrity, all published on February 27, 2026.
3 verified stories tracked
Last mentioned: Feb 27, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Michael McGarrity is most often covered alongside Baldwin, which appears in 2 of these 3 stories. earnings accounts for 1 of the 3 tracked stories, while 2 other categories carry the remainder. We currently track 3 Cross-Sector stories that mention Michael McGarrity, all published on February 27, 2026. Each carries 3 original sources on average.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Michael McGarrity. Shared-story counts are live from our verified record — not editorial picks.
NDA Submission
Planned submission of paltusotine New Drug Application to the FDA.
Phase 3 Initiation
Anticipated start of Phase 3 trials for atumelnant in CAH and Cushing's disease.
Earnings Call
Management confirms commercial readiness and pipeline acceleration.
PATHFNDR-2 Success
Completion of Phase 3 trial for paltusotine in acromegaly with positive results.
Crinetics Pharmaceuticals (CRNX) reported Q4 2025 results, highlighting critical progress in its endocrine pipeline and preparations for the commercial launch of paltusotine. Alongside results from MDxHealth and Baldwin, the earnings cluster reflects a strategic transition for mid-cap healthcare and service firms navigating the 2026 market landscape.
Crinetics Pharmaceuticals reported strong Q4 2025 results, highlighting the successful completion of Phase 3 trials for paltusotine and preparations for a 2026 New Drug Application (NDA). The company is positioning itself for a major commercial pivot in endocrine disorders, supported by a robust balance sheet and positive data for its second lead candidate, atumelnant.
The Q4 2025 earnings reports from Crinetics, MDxHealth, and Baldwin highlight a pivotal shift toward precision diagnostics and specialized endocrine therapies. These results underscore a robust recovery in diagnostic volumes and a maturing pipeline for rare disease treatments entering commercialization phases.
Source: seekingalpha.com · flipboard.com
